Hologic is part of the healthcare sector and trades as part of the medical instruments and equipment industry. The company CEO is Stephen P. Macmillan. Hologic Inc develops, manufactures and supplies diagnostics products, medical imaging systems and surgical products for women’s health. Its products are used in diagnosis of human diseases and screen donated human blood and plasma.
Previous Intraday Trading Performance:
The HOLX stock showed a previous change of 0.37% with an open at 43.22 and a close of 43.61. It reached an intraday high of 43.62 and a low of 42.98.
The stock has a market cap of $12.7b with 291.3m shares outstanding, of which the float is 286.8m shares. Trading volume reached 1,250,864 shares compared to its average volume of 2,306,010 shares. Based on the current average volume and close price, the trading liquidity is good.
Historical Trading Performance:
Over the last five trading days, Hologic shares returned -0.68% and in the past 30 trading days it returned 7.12%. Over three months, it changed 15.07%. In one year it has changed -0.32% and within that year its 52-week high was 45.45 and its 52-week low was 35.10. HOLX stock is 24.25% above its 52 Week Low.
Our calculations show a 200 day moving average of 40.54 and a 50 day moving average of 42.50. Currently HOLX stock is trading 7.56% above its 200 day moving average.
The last annual fiscal EPS for the company was reported at -0.41 that ended on 30th of September 2018. Based on 7 analyst estimates, the consensus EPS for the next quarter is 0.59. The TTM EPS is 2.24, which comes to a TTM PE of 19.47.
The following are the last four quarter reported earnings per share:
Base on our calculations, the intrinsic value per share is 39.22, which means it may be overvalued by -11.20%
Indicators to Watch:
Based on the latest filings, there is 135.60% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.
The current calculated beta is 0.75
Based on last reported financials, the company’s return on equity is -15.39%, return on assets is -5.73%, profit margin is -11.83%, price-to-sales is 3.89 and price-to-book is 5.31.
All scores are out of six:
0 :Valuation Score
0 :Past Performance Score
4 :Financial Strength Score
3 :Future Growth Score
0 :Dividend Score
1 :Overall Score